Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-γ/p38 MAPK signaling

Pharmaceutical Biology

Volumn 52, Issue 9, 2014, Pages 1085-1093

  Liu, Q ^a   Wang, C Y ^a,b   Liu, Z ^c   Ma, X S ^a   He, Y H ^b   Chen, S S ^a   Bai, X Y ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c Department of Hematology Dongying City Center Blood Bank   (China)

Author keywords

Hepatic fibrosis; Herb; HFD; HSYA; Peroxisome proliferator activated receptor

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; GELATINASE A; HYDROXYPROLINE; HYDROXYSAFFLOR YELLOW A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NATURAL PRODUCT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHALCONE; QUINONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; LIPID DIET; LIVER FIBROSIS; LIVER PROTECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARBON TETRACHLORIDE; CHALCONE; DIET, HIGH-FAT; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR GAMMA; QUINONES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84906050806     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.877491     Document Type: Article

References (43)

1. Awad MM, Enslen H, Boylan JM, et al. (2000). Growth regulation via p38 mitogen-activated protein kinase in developing liver. J Biol Chem 275:38716-21.
2. Canbay A, Feldstein AE, Higuchi H, et al. (2003). Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38:1188-98.
3. Cheung KF, Ye DW, Yang ZF, et al. (2009). Therapeutic efficacy of traditional Chinese medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol 124:142-50.
4. Comporti M, Signorini C, Arezzini B, et al. (2008). Isoprostanes and hepatic fibrosis. Mol Aspects Med 29:43-9.
5. Domitrovi R, Jakovac H, Blagojevi G. (2011). Hepatoprotective activity of berberine is mediated by inhibition of TNF-alpha, COX-2, and iNOS expression in CCl(4)-intoxicated mice. Toxicology 280:33-43.
6. Friedman SL. (2003). Liver fibrosis-from bench to bedside. J Hepatol 38:S38-53.
7. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. (2010). Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53:2345-53.
8. Hayasaka A, Saisho H. (1998). Serum markers as tools to monitor liver fibrosis. Digestion 59:381-4.
9. He H, Yang X, Shi M, et al. (2008). Protective effects of hydroxysafflor yellow A on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats. J Pharm Pharmacol 60:115-23.
10. Iimuro Y, Brenner DA. (2008). Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res 25:249-58.
11. Inagaki Y, Okazaki I. (2007). Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56: 284-92.
12. Ishihara K, Miyazaki A, Nabe T, et al. (2012). Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. FASEB J 26: 4111-21.
13. Kohli R, Kirby M, Xanthakos SA, et al. (2010). High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52:934-44.
14. Kohli R, Kirby M, Xanthakos SA, et al. (2013). A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice. Clin Exp Pharmacol Physiol 40:422-30.
15. Lee CH, Olson P, Evans RM. (2003). Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201-7.
16. Lee TF, Lin YL, Huang YT. (2012). Protective effects of kaerophyllin against liver fibrogenesis in rats. Eur J Clin Invest 42:607-16.
17. Lewindon PJ, Pereira TN, Hoskins AC, et al. (2002). The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol 160:1705-15.
18. Li CC, Yang CZ, Li XM, et al. (2012). Hydroxysafflor yellow A induces apoptosis in activated hepatic stellate cells through ERK1/2 pathway in vitro. Eur J Pharm Sci 46:397-404.
19. Li X, Wang X, Han C, et al. (2013). Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway. Free Radic Biol Med 60:168-76.
20. Lin X, Zhang S, Huang Q, et al. (2012). Protective effect of Fufang-Liu- Yue-Qing, a traditional Chinese herbal formula, on CCl4 induced liver fibrosis in rats. J Ethnopharmacol 142:548-56.
21. Miyahara T, Schrum L, Rippe R, et al. (2000). Peroxisome proliferatoractivated receptors and hepatic stellate cell activation. J Biol Chem 275:35715-22.
22. Murawaki Y, Ikuta Y, Koda M, et al. (1996). Clinical significance of serum hyaluronan in patients with chronic viral liver disease. J Gastroenterol Hepatol 11:459-65.
23. Peng Y, Yang H, Zhu T, et al. (2013). The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways. Eur J Clin Invest 43: 358-68.
24. Povero D, Busletta C, Novo E, et al. (2010). Liver fibrosis: A dynamic and potentially reversible process. Histol Histopathol 25:1075-91.
25. Sakaida I, Hironaka K, Kimura T, et al. (2004). Herbal medicine Sho-saiko-to(TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell medicine Sho-saiko-to(TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell. Life Sci 74:2251-63.
26. Seth RK, Kumar A, Das S, et al. (2013). Environmental toxin-linked nonalcoholic steatohepatitis and hepatic metabolic reprogramming in obese mice. Toxicol Sci 134:291-303.
27. She H, Xiong S, Hazra S, Tsukamoto H. (2005). Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 280:4959-67.
28. Sinha-Hikim I, Sinha-Hikim AP, Shen R, et al. (2011). A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice. Exp Mol Pathol 91:419-28.
29. Song L, Zhu Y, Jin M, Zang B. (2013). Hydroxysafflor yellow A inhibits lipopolysaccharide-induced inflammatory signal transduction in human alveolar epithelial A549 cells. Fitoterapia 84:107-14.
30. Sun CY, Pei CQ, Zang BX, et al. (2010). The ability of hydroxysafflor yellow A to attenuate lipopolysaccharide-induced pulmonary inflammatory injury in mice. Phytother Res 24:1788-95.
31. Sun L, Yang L, Xu YW, et al. (2012). Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: Inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption. Brain Res 1473:227-35.
32. Tien YC, Lin JY, Lai CH, et al. (2010). Carthamus tinctorius L. prevents LPS-induced TNFalpha signaling activation and cell apoptosis through JNK1/2-NFkappaB pathway inhibition in H9c2 cardiomyoblast cells. J Ethnopharmacol 130:505-13.
33. Trebicka J, Hennenberg M, Odenthal M, et al. (2010). Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53:702-12.
34. Wang CY, Liu Q, Huang QX, et al. (2013). Activation of PPAR-g is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress. Phytomedicine 20:592-9.
35. Wang JH, Shin JW, Son JY, et al. (2010). Antifibrotic effects of CGX, a traditional herbal formula, and its mechanisms in rats. J Ethnopharmacol 127:534-42.
36. Xiao J, Ho CT, Liong EC, et al. (2013). Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in nonalcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/ Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr [Online]. Available from: http://dx.doi.org/10.1007/s00394- 013-0516-8 [last accessed 21 Mar 2013].
37. Yan Z, Ni Y, Wang P, et al. (2013). Peroxisome proliferatoractivated receptor delta protects against obesity-related glomerulopathy through the P38MAPK pathway. Obesity (Sliver Spring) 21: 538-45.
38. Yang L, Chan CC, Kwon OS, et al. (2006). Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291:G902-11.
39. Yang Y, Yang S, Chen M, et al. (2008). Compound Astragalus and Salvia miltiorrhiza extract exerts anti-fibrosis by mediating TGF-beta/Smad signaling in myofibroblasts. J Ethnopharmacol 118: 264-70.
40. Yu J, Wang Y, Qian H, et al. (2012). Polyprenols from Taxus chinensis var. mairei prevent the development of CCl4-induced liver fibrosis in rats. J Ethnopharmacol 142:151-60.
41. Zeng XX, Bian ZX, Wu TX, et al. (2011). Traditional Chinese medicine syndrome distribution in chronic hepatitis B populations: A systematic review. Am J Chin Med 39:1061-74.
42. Zhang Y, Guo J, Dong H, et al. (2011). Hydroxysafflor yellow A protects against chronic carbon tetrachloride-induced liver fibrosis. Eur J Pharmacol 660:438-44.
43. Zhou Y, Jia X, Qin J, et al. (2010). Leptin inhibits PPARgamma gene expression in hepatic stellate cells in the mouse model of liver damage. Mol Cell Endocrinol 323:193-200.